Summary
AbbVie Inc. (ABBV) has successfully completed a significant underwritten public offering of senior notes totaling $4 billion. This offering includes four tranches with varying maturities and interest rates: $1.25 billion in 4.650% notes due 2028, $1 billion in 4.875% notes due 2030, $1 billion in 5.200% notes due 2035, and $750 million in 5.600% notes due 2055. The issuance was registered under an existing Form S-3ASR registration statement and was finalized on February 25, 2025. These new notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with its existing unsecured debt. The company retains the option to redeem these notes under specific conditions, including at par value after certain dates, with full details outlined in the accompanying indenture. The proceeds from this offering will likely be used to fund corporate activities, potentially including acquisitions, debt refinancing, or general working capital, providing AbbVie with substantial financial flexibility.
Key Highlights
- 1Completed a $4 billion offering of senior unsecured notes.
- 2Notes issued include four series with maturities in 2028, 2030, 2035, and 2055.
- 3Coupon rates range from 4.650% to 5.600%, reflecting market conditions and maturity.
- 4The offering was registered under AbbVie's existing Form S-3ASR registration statement.
- 5Notes are governed by a base indenture supplemented by a new supplemental indenture.
- 6AbbVie has the option to redeem the notes, with specific par call dates and redemption terms.
- 7The notes rank equally with AbbVie's other unsecured and unsubordinated indebtedness.